AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01184222 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: great occipital nerve stimulation
Description: * Active Comparator: Arm Active SENGO The patients will be hospitalised and managed by medication withdrawal and active GONS, surgically temporarily implanted.~* Arm sham SENGO : The patients will be hospitalised and managed by medication withdrawal and sham GONS, surgically temporarily implanted.
Study NCT01536951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009104
Description: administered orally
Study NCT01536951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01536951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: Administered orally
Study NCT04960020 — intervention group
Intervention type: OTHER
Intervention: Retrospective Data Review
Description: Retrospective Data Review
Study NCT02492477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: evaluation of PORT-A-CATH®
Description: in patients in curative setting, clinical assessment, PORT-A-CATH® testing of possibility of saline-administration and blood withdrawal with vacutainer, laboratory assessment
Study NCT02492477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: blocking with Medunasal®-Heparinblock
Description: blocking of the functioning PORT-A-CATH® with heparinized 0,9% NaCl solution
Study NCT02492477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: restoration of PORT-A-CATH® with Alteplase
Description: by malfunction of the PORT-A-CATH® attempting of restoration with Actilyse® according to guidelines
Study NCT01506960 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InfraReDx Lipiscan IVUS
Description: Near Infrared Spectroscopy/Intravascular Ultrasound will be performed following OCT imaging.
Study NCT01817751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given by mouth
Study NCT01817751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproic acid
Description: Given by mouth
Study NCT01817751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate
Description: Given by mouth
Study NCT00514163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine + S-1
Description: gemcitabine on day one and 8th S-1 po days 1 to14 every 3 weeks
Study NCT00514163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: gemcitabine DIV on day one , 8th and 15th
Study NCT01773642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention to support pediatric HIV disclosure
Study NCT01721876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching Volasertib
Study NCT01721876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Volasertib
Study NCT01721876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cytarabine
Description: Cytarabine
Study NCT01721876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine
Study NCT02849197 — intervention group
Intervention type: PROCEDURE
Intervention: surgery for pilonidal sinus disease
Description: surgical treatment of pilonidal sinus disease via primary closure, Limberg flap0 technique and Modified Limberg flap technique.
Study NCT01473563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered intravenously
Study NCT01235793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: The DRBEAT regimen will be similar to RBEAM. Rituximab and Carmustine will be given Day -6. Etoposide and Cytarabine will be given on Days -5 to -2. Temozolomide will be given via divided doses over five days starting on Day -5 to Day -1. A dose escalation design, known as EWOC (Escalation with overdose control) will be used to determine the target dose of temozolomide for this study. The starting dose given over five days will begin at 250mg/m2 (cumulative total dose of 1250 mg/m2), as previous data indicates this to be a safe dose. Based on the reported Dose Limiting toxicities from the previous patients, the EWOC statistical modeling will be performed to determine the next dose level.
Study NCT01191866 — intervention group
Intervention type: BEHAVIORAL
Intervention: psychosocial intervention
Description: The interventions will include an art therapist, a social worker and volunteer work under the supervision of a diabetes nurse. These therapies will be given to selected patients based on individual needs. We will use existing questionnaires in order to identify problematic areas and quantify quality of life
Study NCT01537536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EndoTAG-1
Description: EndoTAG-1 (22 mg/m2 liposomal paclitaxel) + Paclitaxel (70 mg/m2) Weekly i.v. infusions of EndoTAG-1 and paclitaxel for 12 weeks followed by subsequent treatment with the standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2) once every 3 weeks for 3 cycles of therapy followed by surgery.
Study NCT00578136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine, 0.25%, dose amount is weight based, injection is divided per dise with rectus sheath injection or with local infiltration of the operative area.
Study NCT01202279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guaifenesin
Description: 1200 mg guaifenesin and 120 mg pseudoephedrine HCl bid for 7 days
Study NCT01202279 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo bid for 7 days
Study NCT03970850 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: NeuMoDx CT/NG Assay
Description: NeuMoDx CT/NG Assay as implemented on NeuMoDx 288 Molecular System and NeuMoDx 96 Molecular System
Study NCT03970850 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FDA-cleared NAATs
Description: Testing swabs and urine specimen from both male and female subjects on the FDA-cleared NAATs
Study NCT01177683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Phase I component:~Bendamustine escalating cohorts to determine MTD, IV over 1 hour, Days 1 and 4
Study NCT01177683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Phase I and II components:~Pegylated liposomal doxorubicin, 30 mg/m2 IV over 1 hour, Day 4
Study NCT01177683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Phase I and II components:~Bortezomib 1.3 mg/m2 IV bolus, Days 1, 4, 8, and 11
Study NCT01177683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Phase II component:~Bendamustine at at MTD IV over 1 hour, Days 1 and 4
Study NCT01177683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Phase II component:~Filgrastim (if defined in MTD) 5 µg/kg/day SC, starting day 6 until neutrophil recovery to ANC >1000
Study NCT02575053 — intervention group
Intervention type: PROCEDURE
Intervention: assessment of a new latex protocol
Description: 1. All powdered latex surgical gloves are removed from the operating theatres, recovery room and surroundings starting from 01-07-2015 in order to create a latex safe environment.~   Steps 2 and 3 remain unchanged in respect to ASA( American Society of Anesthesiologists) protocol.~2. Removal of all materials containing latex from the resuscitation carts.~3. Further requirements in case of latex allergic patients:~   * Identification of patients with (suspected) latex allergy.~  * All materials used during the procedure (catheters, drains, monitoring equipment,...) should be checked for latex.~All latex containing materials should be removed from the room and latex free alternatives should be available.~* All staff present in the room should use latex free synthetic gloves.~* Operating tables and supports should be made of latex free material or should be covered with blankets.~* The entire OR staff is thoroughly educated concerning the latex safe protocol.
Study NCT00966420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traction assisted endoscopic mucosa resection
Description: A haemoclip is connected to suture material and will be fixed (next) to a polyp to allow traction and lifting the lesion in order to facilitate its resection with a loop.
Study NCT02330822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: This material is going to be injected into the extraction socket in order to promote bone healing.
Study NCT04171518 — intervention group
Intervention type: DEVICE
Intervention: Catalys Precision Laser System
Description: Cataract surgeons to create a precise anterior capsulotomy and/or subsequent fragmentation (phacofragmentation) of the crystalline lens using the Catalys Precision Laser System
Study NCT02219321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine infusion
Description: Lidocaine intravenous 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg /kg /hour for 4 hours
Study NCT02219321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline infusion
Description: A continuous intravenous infusion of saline at the same volume with lidocaine infusion for 4 hours
Study NCT02081404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: standard dose of proton pump inhibitor by mouth once a day for 30 days
Study NCT02081404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT03001960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preloading before TAVI
Description: Preloading with Aspirin and Clopidogrel before TAVI
Study NCT03001960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postloading after TAVI
Description: Postloading with Aspirin and Clopidogrel after TAVI
Study NCT01898936 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pretreatment with CO2 laser before photodynamic therapy
Description: The treatment will be a field treatment performed with a 30 W Lutronic carbondioxide laser; covering one of the symmetrical treatment areas allocated to fractional carbondioxide laser.~The laser settings will be as follows:~The fluence will initially be 10mJ/cm2 delivered with a 120 micron tip (producing 120 micron ablative columns) with 5% density. The fluence will be increased until the patient experiences pain (pain indicating penetration to dermis), and then reduced to maximum fluence without pain. Allocation to laser therapy is blinded for the future evaluator.~The PDT procedure includes application of Metvix cream on the skin on both symmetrical areas with a thickness of approximately 1 mm, plastic covering for 30 minutes before entering daylight for 2 hours.
Study NCT01898936 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Only photodynamic therapy
Study NCT02254577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endometrin® plus Progesterone in Oil (PIO)
Study NCT02254577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone in Oil (PIO) Only
Study NCT00310804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV)
Description: One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 1
Study NCT00310804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV)
Description: One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 2
Study NCT00310804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV)
Description: One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 3
Study NCT00310804 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Egg-Derived Trivalent Subunit Influenza Vaccine (TIV)
Description: One single 0.5ml intramuscular injection of Egg Derived Trivalent Subunit Influenza Vaccine (TIV).
Study NCT03778853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Anlotinib Hydrochloride ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.~Other Name: AL3818
Study NCT00445224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip Progressive Resistive Exercise
Description: Hip Progressive Resistance Exercise program will be carried out by subjects under supervision once a week and then performed at home 2 additional times at home without supervision. Exercises focus on strengthening hip abduction ad external rotation musculature.
Study NCT00445224 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quad Progressive Resistive Exercises
Description: Quad Progressive Resistive Exercise program will be carried out by subjects under supervision once a week and then performed at home 2 additional times at home without supervision. Exercises focus on strengthening quadriceps musculature with straight leg raises and quadriceps isometrics.
Study NCT03327012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of Panlongqi Tablet
Description: Panlongqi Tablet:1.2g,3times a day, oral, for 4 weeks.
Study NCT03327012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment of Panlongqi placebo
Description: Panlongqi placebo:1.2g,3times a day, oral, for 4 weeks.
Study NCT02366559 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyfrecator
Study NCT02366559 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 532 nm Q-switched Nd:YAG laser
Study NCT03062592 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pine nut oil
Description: Subjects are supplemented with either no oil, hydrolyzed oil or non-hydrolyzed oil in combination with an OGTT
Study NCT00745693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endothelin-1
Description: Intra-arterial infusion of Endothelin-1 at 5pmol/min for 1 hour during venous occlusion plethysmography
Study NCT00745693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-123 and BQ-788
Description: 1 hour intra-arterial infusion of BQ-123 at 10nmol/min followed by co-infusion of BQ-788 at 1nmol/min for a further hour during forearm venous occlusion plethysmography
Study NCT02874365 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic biopsies
Description: intestinal biopsies
Study NCT02874365 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Endoscopic biopsies
Description: intestinal biopsies
Study NCT01671423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: See Prednisone arm description
Study NCT01671423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See Placebo arm description
Study NCT00981513 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent live attenuated seasonal influenza vaccine
Description: One dose
Study NCT00981513 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monovalent live attenuated pandemic influenza vaccine
Description: One dose
Study NCT00981513 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: One dose
Study NCT00943579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuvan®
Description: Brand-name Kuvan® (sapropterin) will be administered to all subjects at a dose of 20 mg/kg/day for 16 weeks.
Study NCT04201990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab and Apatinib
Description: Camrelizumab, iv, Q3W; Apatinib, po, QD
Study NCT01855451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Study NCT01855451 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: RT (70 Gy in 35 fractions)
Study NCT01855451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study NCT02401321 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Complete Taking Care of Her program
Study NCT02401321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caregiver-Assisted Training
Description: Complete Taking Care of Her program
Study NCT02401321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02401321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03294525 — intervention group
Intervention type: DRUG
Intervention: Escitalopram Pill
Description: escitalopram 10\~20mg/day
Study NCT03294525 — intervention group
Intervention type: DRUG
Intervention: Duloxetine
Description: duloxetine 30\~120mg/day
Study NCT03294525 — intervention group
Intervention type: DRUG
Intervention: Mirtazapine Pill
Description: Mirtazapine 15\~45mg/day
Study NCT03294525 — intervention group
Intervention type: DRUG
Intervention: Other Antidepressants
Study NCT01671813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Brentuximab vedotin will be given intravenously as outlined in treatment arm.
Study NCT03926845 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isobutylamido-thiazolyl-resorcinol Cream 0.2%
Description: Each bottle contains Isobutylamido-thiazolyl-resorcinol cream 0.2% to be applied on the entire face twice daily for 12 weeks.
Study NCT03926845 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Each bottle contains vehicle cream to be applied on the entire face twice daily for 12 weeks.
Study NCT02269787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Telephone Monitoring
Description: Detox inpatients in the ETM condition will be expected to complete one session while in detox and one 15-minute telephone call per week for 12 weeks (plus usual care).
Study NCT01038804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM155
Description: intravenous infusion
Study NCT01038804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: intravenous infusion
Study NCT01038804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: intravenous infusion
Study NCT04636424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: assesment of gait
Description: speed and weight distribution during gait
Study NCT02558673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TMAO dietary precursors
Study NCT02558673 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (or active comparator)
Study NCT04532385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea extract
Description: 400 mg capsule
Study NCT04532385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 mg capsule
Study NCT03800888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily SMS reminders for TB patients
Description: Daily SMS Medication reminders will be sent to TB patients to remind them take their medications.
Study NCT03800888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS Notifications for social supporters
Description: SMS Notifications will be sent to social supporters to assit TB patients take their medication
Study NCT03800888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly SMS remiders
Description: Weekly SMS reminders sent to TB patients to remind them take medication
Study NCT03585218 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inhalation of essential oils
Description: Intervention Inhalation of essential oils: From the T1 (2nd Cycle CT), Experimental Group Arms will undergo the inhalation of the hedonic aroma selected by them at the time of chemotherapy (among several types of aromas). It is intended that the participant, when receiving the CT, inhales the aroma phase-in and under the investigator's observation until the end of the treatment (about two hours). The inhalation of essential oils will occur using cotton rolls impregnated with the selected oil. The control group is not subject to intervention during chemotherapy treatment.
Study NCT00940979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of Integuseal sealant
Description: Microbial sealant (integuseal) applied with a sponge applicator
Study NCT00777777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eSVS, saphenous vein supporting mesh
Description: Surgical coronary artery bypass grafting to the right coronary artery and the circumflex coronary artery with saphenous vein grafts, one will be supported by the eSVS(TM).
Study NCT03926689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS messages
Description: A package of at least monthly SMS messages delivered to all adults in households with an individual in the 1000-day period between pregnancy and a child turning 2 years of age.
Study NCT03926689 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard SII SBCC
Description: Home visits/IPC; community events including food demo and key life events; and Bhanchhin Aama radio program episodes